跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REFRESH OPTIVE FUSION SENSITIVE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
REFRESH OPTIVE FUSION SENSITIVE
Authorized
STANDARD
REFRESH OPTIVE FUSION SENSITIVE
Allergan, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1b952e6ac7a2c095
Company
Allergan, Inc.
Type
Standard
Approval Details
Approval Id
1b952e6ac7a2c095
Drug Approval Canada Name
REFRESH OPTIVE FUSION SENSITIVE
Product Name
REFRESH OPTIVE FUSION SENSITIVE
Status
Cancelled Post Market
Status Date
2024-06-20
Original Market Date
2016-04-26
Din
02450534
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Ophthalmic
Schedule
OTC
Ahfs
52:13.00*
Atc Original
S01XA20 ARTIFICIAL TEARS AND OTHER INDIFFERENT PREPARATIONS.
Atc Name
s 01 xa 20
Aig Number
0251696003
Company Name
Allergan, Inc.
Company Address
300, 1380 Rodick Road, Markham, Ontario, Canada, L3R 4G5
Company Detail Path
/organization/allergan-inc
Company Information
Pharmaceutical Company Name
Allergan, Inc.
Name Zh
艾尔建 (美国)
Country Name
United States
Province Name
Illinois
City Name
north chicago,illinois,country_us
Address
1 N Waukegan Rd
Website
https://thespotlyte.com/index.html
Active Ingredients
GLYCERINE
1 % / W/V
CARBOXYMETHYLCELLULOSE SODIUM
0.5 % / W/V
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1b952e6ac7a2c095
Type
Standard
Back to Health Canada Approvals